BioCentury
ARTICLE | Financial News

EIP gets $20.5M to develop AD candidate

May 18, 2018 7:08 PM UTC

CNS company EIP Pharma LLC (Cambridge, Mass.) raised $20.5 million on May 16 in a series B round led by new investor Access Industries. Other individual investors participated.

EIP told BioCentury it expects the funding to last through 2019. The company is enrolling 150 patients in the Phase IIb REVERSE-SD trial evaluating neflamapimod to treat Alzheimer's disease. Data are due in 2H19...